Meta description: A regulatory overview of portable ultrasound triage for breast lumps in a multicenter trial sponsored by IARC and Dharmais National Cancer Center Hospital.
Published February 13, 2026.
The source text describes a study focused on breast cancer and uses a portable ultrasound device as a diagnostic test to triage women who present with palpable lumps during clinical breast examination. The trial is sponsored by the International Agency for Research on Cancer and Dharmais National Cancer Center Hospital and is actively recruiting participants. The ClinicalTrials.gov entry can be accessed for full details at NCT07407153.
The trial is registered on ClinicalTrials.gov under identifier NCT07407153. Access the details here: ClinicalTrials.gov NCT07407153.
What changed for triage in clinical breast examination with portable ultrasound?
The trial explores using a handheld imaging device to aid triage decisions after clinical breast examination. The aim is to determine whether imaging can help differentiate lesions that require additional imaging or biopsy from those that can be monitored with standard care. The description reflects a regulatory approach that emphasizes the diagnostic support role of a portable ultrasound tool rather than a replacement for established workups. Clinicians may see decisions moved earlier in the care pathway if imaging characteristics align with predefined criteria for action where safety data supports use.
Intended use and regulatory framing
The trial records describe the portable ultrasound device as a diagnostic test to assist triage after breast examination. This framing aligns with regulatory expectations to document intended purpose and safety for imaging devices used in clinical decision making. No efficacy claims are stated in the record, and outcomes will be determined by later trial results and regulatory review processes.
How does portable ultrasound fit into regulatory expectations for diagnostic devices?
From a regulatory perspective, the exercise mirrors the process of collecting performance and safety data for a diagnostic imaging tool used at the point of care. The MDR style emphasis is on clear statement of intended use, a defined risk profile, and a plan for evidence generation on diagnostic performance and risk management. The current description does not present final performance metrics; it signals the need for rigorous data to support future regulatory submissions or post market considerations.
Regulatory framing and data expectations
Annex XIV of the MDR calls for documented intended purpose and evidence on performance and safety for devices used in clinical decision making. In this trial the focus is on a portable ultrasound device used in triage. Data from recruitment and imaging findings will inform risk controls, labeling, and potential labeling updates if results support broader use in care pathways.
Who funds and leads this trial?
The study is listed with sponsorship by the International Agency for Research on Cancer and Dharmais National Cancer Center Hospital. This international collaboration includes academic and clinical institutions that aim to generate robust data on triage strategies using portable imaging. The source text notes that recruitment is ongoing, indicating that participant enrollment is still in progress at the time of reporting.
Study leadership and design notes
Details about study design beyond the described diagnostic test are not provided in the source text. The emphasis remains on data collection for imaging based triage decisions and the safety and risk management implications that follow from using a handheld device in breast care. Observers will monitor imaging interpretation consistency and how results influence clinical pathways.
What are the performance and safety considerations?
Specific performance metrics such as sensitivity or specificity are not disclosed in the source text. The regulatory mindset requires careful evaluation of how well the portable ultrasound device distinguishes between lesions that require escalation and those that do not. Safety considerations include potential user training needs, image quality issues, device handling, and patient comfort during scanning. The trial’s outcomes will shape recommendations for operator qualification and device labeling if results support broader use.
Operator training and workflow impact
Effective integration into clinical practice depends on standardized training and defined workflow. The trial description implies a setting where clinicians use a portable ultrasound device to inform triage, which carries implications for time to treatment, referral patterns, and patient experience. Compliance with regulatory expectations will require documentation of training, competency assessment, and ongoing monitoring of device performance in real world use.
FAQ
- What is the purpose of the trial NCT07407153? The trial assesses the use of a portable ultrasound device to aid triage after a breast examination.
- Who sponsors the trial? The International Agency for Research on Cancer and Dharmais National Cancer Center Hospital are listed sponsors.
- Where can I find more information? The ClinicalTrials.gov entry provides official trial details and status.
Conclusion
The trial represents a cautious step toward incorporating portable imaging in triage workflows. Regulatory considerations will depend on the completeness of performance and safety data and on the clarity of the intended use. Clinicians and regulatory teams should monitor forthcoming results and plan for risk management and labeling updates if data support broader deployment.
Disclaimer
This article is intended for professional audiences and is not legal advice. Regulatory decisions depend on jurisdiction and applicable law. Readers should consult official regulatory guidance for their region.
Announcement
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07407153?term=medical+device